insight
✂️ 성형 🏥 중증 🌐 전체
← 뒤로

Matching-Adjusted Indirect Comparisons of PARP Inhibitor Combinations in Metastatic Castration-Resistant Prostate Cancer Across Key Populations.

2/5 보강
The oncologist 📖 저널 OA 97.7% 2022: 2/2 OA 2023: 2/2 OA 2024: 15/15 OA 2025: 88/89 OA 2026: 105/109 OA 2022~2026 2026 OA Prostate Cancer Treatment and Resear
Retraction 확인
출처
PubMed DOI OpenAlex 마지막 보강 2026-04-29

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
2 patients meeting PROpel/MAGNITUDE eligibility criteria were included; remaining patients were reweighted to align on key baseline characteristics.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] MAICs showed improved clinical benefit with TALA+ENZA versus OLAP+AAP and NIRA+AAP across multiple mCRPC populations and endpoints. Despite limitations of indirect comparisons, findings support TALA+ENZA as a first-line treatment option for mCRPC.
OpenAlex 토픽 · Prostate Cancer Treatment and Research Prostate Cancer Diagnosis and Treatment PARP inhibition in cancer therapy

Castro E, Wang D, Paganelli S, Haltner A, Su N, Kirker M, Chang J, Samjoo IA

📖 무료 전문 🔓 OA PDF oa
PubMed ↗ DOI ↗ BibTeX ↓ RIS ↓
📝 환자 설명용 한 줄

[BACKGROUND] Without head-to-head trials comparing talazoparib plus enzalutamide (TALA+ENZA), olaparib plus abiraterone acetate and prednisone (OLAP+AAP), and niraparib plus abiraterone acetate and pr

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • HR 0.747

이 논문을 인용하기

↓ .bib ↓ .ris
APA Elena Castro, Di Wang, et al. (2026). Matching-Adjusted Indirect Comparisons of PARP Inhibitor Combinations in Metastatic Castration-Resistant Prostate Cancer Across Key Populations.. The oncologist. https://doi.org/10.1093/oncolo/oyag143
MLA Elena Castro, et al.. "Matching-Adjusted Indirect Comparisons of PARP Inhibitor Combinations in Metastatic Castration-Resistant Prostate Cancer Across Key Populations.." The oncologist, 2026.
PMID 41992842 ↗
DOI 10.1093/oncolo/oyag143

Abstract

[BACKGROUND] Without head-to-head trials comparing talazoparib plus enzalutamide (TALA+ENZA), olaparib plus abiraterone acetate and prednisone (OLAP+AAP), and niraparib plus abiraterone acetate and prednisone (NIRA+AAP) as first-line treatments for metastatic castration-resistant prostate cancer (mCRPC), treatment selection remains challenging. This study estimated the relative efficacy of TALA+ENZA versus OLAP+AAP and NIRA+AAP in unselected, homologous recombination repair (HRR)-deficient, and BRCA-mutated (BRCAm) populations.

[METHODS] Unanchored matching-adjusted indirect comparisons (MAICs) were conducted using individual patient data from TALAPRO-2 (TALA+ENZA) and published summary-level data from PROpel (OLAP+AAP) and MAGNITUDE (NIRA+AAP). TALAPRO-2 patients meeting PROpel/MAGNITUDE eligibility criteria were included; remaining patients were reweighted to align on key baseline characteristics. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated for radiographic progression-free survival (rPFS) and overall survival (OS).

[RESULTS] In unselected patients, TALA+ENZA significantly prolonged rPFS versus OLAP+AAP (HR: 0.747; 95% CI: 0.583, 0.957), with no OS difference (HR: 0.821; 95% CI: 0.649, 1.039). In HRR-deficient patients, TALA+ENZA significantly prolonged rPFS versus OLAP+AAP (HR: 0.648; 95% CI: 0.423, 0.992), with no OS difference (HR: 0.834; 95% CI: 0.569, 1.223). Comparisons with OLAP+AAP in BRCAm were infeasible. Compared with NIRA+AAP, TALA+ENZA significantly prolonged rPFS and OS in HRR-deficient (HR: 0.406; 95% CI: 0.251, 0.655; HR: 0.554; 95% CI: 0.340, 0.902) and BRCAm patients (HR: 0.394; 95% CI: 0.222, 0.698; HR: 0.472; 95% CI: 0.247, 0.902).

[CONCLUSIONS] MAICs showed improved clinical benefit with TALA+ENZA versus OLAP+AAP and NIRA+AAP across multiple mCRPC populations and endpoints. Despite limitations of indirect comparisons, findings support TALA+ENZA as a first-line treatment option for mCRPC.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (4)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🔓 OA PDF 열기